The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.

@article{Koopmeiners2017TheRC,
  title={The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.},
  author={Joseph S Koopmeiners and Andrew Wey},
  journal={Journal of biopharmaceutical statistics},
  year={2017},
  volume={27 6},
  pages={
          1028-1042
        }
}
The primary object of a Phase I clinical trial is to determine the maximum tolerated dose (MTD). Typically, the MTD is identified using a dose-escalation study, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher dose levels until the MTD is identified. The continual reassessment method (CRM) is a popular model-based dose-escalation design, which utilizes a formal model for the relationship between dose and toxicity to guide… CONTINUE READING